// App-Quantinova.ai

5051 : Efficacy and tolerability of first-line abiraterone + prednisone (ABI) versus enzalutamide (ENZ) for metastatic castration-resistant prostate cancer (mCRPC) in men 80 years: A retrospective cohort study.

Researchers

Presenter

  • Daniel Khalaf

Principal Investigators

  • Kevin Zou

  • Werner J. Struss

  • Bernhard J. Eigl

  • Christian K. Kollmannsberger

  • Daygen L. Finch

  • Krista Noonan

  • Joanna Vergidis

  • Muhammad Zulfiqar

  • Kim N. Chi

Medical Centers

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

  • British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna, BC, Canada

  • British Columbia Cancer Agency, Abbotsford Centre, Vancouver, BC, Canada

  • BC Cancer Agency Vancouver Island Centre, Victoria, BC, Canada

  • BC Cancer Agency, Abbotsford, BC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Prostate specific antigen

  • ZFP36 Ring Finger Protein Like 1

  • Apoptotic body index

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Prednisone

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved